![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
,3
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and
* Department of Human Physiology, Division of Nephrology, University of California, Davis, CA 95616;
School of Pharmacy, Department of Molecular Pharmacology and Toxicology, University of Southern California, Los Angeles, CA 90089-9121
3To whom correspondence should be addressed. E-mail: packer{at}usc.edu.
Lycopene has repeatedly been shown to inhibit the growth of human prostate cells in vitro. However, previous studies with lycopene have focused on cancer specimens, and it is still unclear whether this carotenoid affects the growth of normal human prostate cells as well. Therefore, we investigated the effects of lycopene on normal human prostate epithelial cells (PrEC) by treating them with synthetic all-E-lycopene (up to 5 µmol/L) and assessing proliferation via [3H]thymidine incorporation. The effects of lycopene on cell cycle progression were investigated via flow cytometry. To elucidate whether lycopene modulates cyclins involved in cell cycle progression, protein expressions of cyclins D1 and E were analyzed. The results show that lycopene significantly inhibited the growth of PrEC in a dose-dependent fashion. Flow cytometry revealed a significant cell cycle arrest in the G0/G1 phase. This effect was confirmed by inhibition of cyclin D1 protein expression, whereas cyclin E levels remained unchanged. The results demonstrate that lycopene inhibits growth of nonneoplastic PrEC in vitro. We hypothesize that lycopene might likewise inhibit the growth of prostatic epithelial cells in vivo. This might have an effect on prostate development and/or on enlargement of prostate tissue as found in benign prostate hyperplasia, a potential precursor of prostate cancer.
KEY WORDS: • lycopene • prostate • prostate hyperplasia • cell cycle • cell proliferation
This article has been cited by other articles:
|
|
 |
|
  S. Schwarz, U. C. Obermuller-Jevic, E. Hellmis, W. Koch, G. Jacobi, and H.-K. Biesalski Lycopene Inhibits Disease Progression in Patients with Benign Prostate Hyperplasia J. Nutr., January 1, 2008; 138(1): 49 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Hantz, L. F. Young, and K. R. Martin Physiologically Attainable Concentrations of Lycopene Induce Mitochondrial Apoptosis in LNCaP Human Prostate Cancer Cells Experimental Biology and Medicine, March 1, 2005; 230(3): 171 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tang, T. Jin, X. Zeng, and J.-S. Wang Lycopene Inhibits the Growth of Human Androgen-Independent Prostate Cancer Cells In Vitro and in BALB/c Nude Mice J. Nutr., February 1, 2005; 135(2): 287 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Campbell, K. Canene-Adams, B. L. Lindshield, T. W.-M. Boileau, S. K. Clinton, and J. W. Erdman Jr Tomato Phytochemicals and Prostate Cancer Risk J. Nutr., December 1, 2004; 134(12): 3486S - 3492S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Asai, M. Terasaki, and A. Nagao An Epoxide-Furanoid Rearrangement of Spinach Neoxanthin Occurs in the Gastrointestinal Tract of Mice and In Vitro: Formation and Cytostatic Activity of Neochrome Stereoisomers J. Nutr., September 1, 2004; 134(9): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
